Bonaire, Sint Eustatius and Saba vs Guadeloupe: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Bonaire, Sint Eustatius and Saba
0.2%
in 2024
Guadeloupe
0.2%
in 2024
Bonaire, Sint Eustatius and Saba rank
98th
Guadeloupe rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Bonaire, Sint Eustatius and Saba
- Guadeloupe
How they compare
Bonaire, Sint Eustatius and Saba currently reports 0.2% against 0.2% in Guadeloupe, a difference of 0.0%.
Across all 10 years both countries report, Guadeloupe has been ahead every year.
Bonaire, Sint Eustatius and Saba ranks 98th and Guadeloupe ranks 98th of 246 countries.
Head to head by decade
| Decade | Bonaire, Sint Eustatius and Saba | Guadeloupe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Bonaire, Sint Eustatius and Saba or Guadeloupe?
- Bonaire, Sint Eustatius and Saba, at 0.2% against 0.2% in Guadeloupe as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Bonaire, Sint Eustatius and Saba and Guadeloupe?
- 0.0%, with Bonaire, Sint Eustatius and Saba ahead.
- How many years of comparable data are there for Bonaire, Sint Eustatius and Saba and Guadeloupe?
- 10 years are reported by both, from 2015 to 2024.
- How do Bonaire, Sint Eustatius and Saba and Guadeloupe rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Bonaire, Sint Eustatius and Saba ranks 98th and Guadeloupe ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.